36.54
+0.09(+0.25%)
Currency In USD
| Previous Close | 36.45 |
| Open | 36.76 |
| Day High | 36.76 |
| Day Low | 36.27 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 1.91M |
| Average Volume | 2.25M |
| Market Cap | 6.83B |
| PE | -8.08 |
| EPS | -4.52 |
| Moving Average 50 Days | 37.96 |
| Moving Average 200 Days | 41.73 |
| Change | 0.09 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,264.36 as of August 20, 2025 at a share price of $36.54. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $1,632.71 as of August 20, 2025 at a share price of $36.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report fina
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
GlobeNewswire Inc.
Jul 24, 2025 8:00 PM GMT
REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a pee
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been prev